Dilaforette AB

Sevuparin – A Designed Anti-Adhesive
In several therapeutic conditions, obstructions in the microvascular occur and lead to reductions in blood flow, thereby causing damages, e.g. ischemia and organ damage.

Dilaforette’s proprietary polysaccharide drug, sevuparin, has a multimodal mechanism of action, as it
• binds to several adhesion receptors
• blocks or reverses cell to cell interactions
• reduces ability for cells to adhere and form obstructions

Sevuparin thus have the potential to restore blood flow and prevent further microvascular obstruction. It has been derived from heparin and has been designed to retain all anti-adhesives effects of heparin, while minimizing the anti-coagulant properties in order to reduce the risk of bleeding.


Dilaforette is currently developing sevuparin for Sickle-Cell Disease as well as severe malaria, two indications with large unmet medical need.

Sickle-Cell Disease
Sickle-Cell Disease (SCD) is a painful and life-shortening disease. In SCD, adherence of sickled red blood cells to the endothelium of blood vessels lead to restricted blood flow. This leads to acute and painful Vaso-Occlusive Crises (VOC), which is the clinical hallmark of the disease. The disease is also associated with morbidity and increase mortality, e.g. cardiopulmonary complication and acute organ damage.

There is currently no approved therapy for treatment of acute VOC besides pain management. Sevuparin has demonstrated efficacy in preclinical models of acute VOCs and is ready to enter phase II

Severe Malaria
Despite improved prevention and treatment in malaria, there are still about 1 million deaths per year, mostly in children in Africa. In severe malaria, the blood circulation is hampered due to massive obstruction of parasitized red blood cells that stick to the wall of the smallest blood vessels and to uninfected red blood cells. This constitutes the central feature in the severe disease development and is a direct cause of coma and death. There is today no drug available that reverses the obstruction of the small blood vessels. Dilaforette recently published data from an exploratory phase I/II study in uncomplicated falciparum malaria, where sevuparin was found to be safe and well tolerated. The results also indicated important early anti-adhesive effects of sevuparin.

Sevuparin is currently in phase II in uncomplicated malaria.

Business Model
Dilaforette will develop sevuparin to clinical proof-of-concept and intends thereafter to seek a partner for the development and the commercialization of the drug.

A Swedish drug development company, founded by leading scientists in malaria from Karolinska Institute as well as leading experts in the field of heparin and drug development from Uppsala University and the Swedish pharmaceutical industry together with Karolinska Innovation

Dilaforette AB
+46 8 524 847 01